- Stocks
- Pharma & Healthcare
- SAGILITY
SAGILITY share price
NSE: SAGILITYPharma & HealthcareHealth Information Services
SAGILITY at a glance
SAGILITY (NSE: SAGILITY) closed at ₹43.95 on 19 Oct 2026, down 3.09% on the day. With a market capitalisation of ₹20,574 Cr, it ranks 353rd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Health Information Services.
At its last close the stock traded at 22.2× trailing earnings, against a return on equity of 9.6% in FY26. Over the past year the share price has fallen 5.2%. Its 52-week range is ₹35.83 (23 Mar 2026) to ₹57.89 (30 Oct 2025); the last close is 24.1% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹1,963 Cr (+27.6% year on year) and net profit ₹217 Cr (+45.9%), on a consolidated basis. Promoters held 50.95% of the company as of 30 Jun 2026; 100.00% of promoter shares were pledged.
Key numbers
- Market cap
- ₹20,574 CrRank 353 on NSE
- P/E (trailing)
- 22.2×
- Price to book
- 1.93×FY26
- EPS (TTM)
- ₹2.12to Q1 FY27
- ROE
- 9.6%FY26
- ROCE
- 12.8%FY26
- Debt to equity
- 0.11FY26
- Net profit margin
- 12.9%FY26
- Book value / share
- ₹20.64FY26
- 52-week high
- ₹57.8930 Oct 2025
- 52-week low
- ₹35.8323 Mar 2026
- 1-year return
- −5.2%
- RSI (14-day)
- 48
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.09% | +2.0% | −1.6% | +5.9% | −5.2% |
SAGILITY quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,325 Cr | ₹1,453 Cr | ₹1,568 Cr | ₹1,539 Cr | ₹1,659 Cr | ₹1,971 Cr | ₹2,024 Cr | ₹1,963 Cr |
| Revenue YoY | +21.1% | +15.3% | +22.2% | +25.8% | +25.2% | +35.7% | +29.1% | +27.6% |
| Net profit | ₹117 Cr | ₹217 Cr | ₹183 Cr | ₹149 Cr | ₹251 Cr | ₹268 Cr | ₹258 Cr | ₹217 Cr |
| Net profit YoY | +235.6% | +207.2% | +127.6% | +566.5% | +113.8% | +23.4% | +41.2% | +45.9% |
| Net margin | 8.9% | 14.9% | 11.6% | 9.7% | 15.1% | 13.6% | 12.7% | 11.0% |
| EPS | ₹0.25 | ₹0.46 | ₹0.39 | ₹0.32 | ₹0.53 | ₹0.57 | ₹0.56 | ₹0.46 |
SAGILITY financials
| Item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | ₹923 Cr | ₹4,218 Cr | ₹4,754 Cr | ₹5,570 Cr | — |
| Operating profit | −₹2 Cr | ₹186 Cr | ₹242 Cr | ₹760 Cr | — |
| Net profit | −₹5 Cr | ₹144 Cr | ₹228 Cr | ₹539 Cr | — |
| EPS (₹) | ₹0.00 | ₹0.00 | ₹1.00 | ₹1.00 | — |
| Cash from operations | −₹32 Cr | ₹857 Cr | ₹973 Cr | ₹1,214 Cr | — |
| Total debt | ₹4,184 Cr | ₹2,324 Cr | ₹1,665 Cr | ₹567 Cr | ₹381 Cr |
| Shareholders' equity | −₹2,671 Cr | −₹491 Cr | ₹6,443 Cr | ₹8,336 Cr | ₹9,659 Cr |
SAGILITY shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 82.39% | 67.38% | 67.38% | 50.95% | 50.95% | 50.95% |
| Foreign institutions | 3.39% | 5.99% | 5.59% | 10.25% | 10.02% | 9.99% |
| Domestic institutions | 7.48% | 14.06% | 14.88% | 21.36% | 22.29% | 21.42% |
| Non-institutions | 6.74% | 12.58% | 12.15% | 17.44% | 16.74% | 17.64% |
| Promoter shares pledged | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
SAGILITY vs peers
The listed Pharma & Healthcare companies nearest to SAGILITY by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| PGHHProcter Gamble | ₹7,110.00 | −0.84% | −50.1% | ₹23,080 Cr | 26.9 | 62.3% |
| PIRPHYTOPiramal Phytoca | — | — | — | ₹21,083 Cr | — | — |
| SAGILITYSAGILITY | ₹43.95 | −3.09% | −5.2% | ₹20,574 Cr | 22.2 | 9.6% |
| IGLIndraprastha | ₹142.29 | −0.51% | −34.1% | ₹19,921 Cr | 12.9 | 27.0% |
| GRANULESGranules India | ₹802.85 | −2.45% | +41.1% | ₹19,894 Cr | 32.8 | 11.7% |
| COHANCECohance Lifesciences | ₹456.50 | −1.76% | −49.6% | ₹17,464 Cr | 97.8 | 15.8% |
| PFIZERPfizer | ₹3,805.50 | −0.12% | −28.4% | ₹17,409 Cr | 24.1 | 17.2% |
Ask anything about SAGILITY
Pivot answers on the live chart with evidence you can check, and tests strategies against SAGILITY's own history. Try: “Why has SAGILITY moved over the last three months?” · “Backtest a 50-day moving-average crossover on SAGILITY over five years” · “Compare SAGILITY with PGHH on margins and valuation”
Frequently asked questions about SAGILITY
What is the share price of SAGILITY today?
SAGILITY (NSE: SAGILITY) last closed at ₹43.95 on 19 Oct 2026. Its 52-week high is ₹57.89 and its 52-week low is ₹35.83.
What is the market cap of SAGILITY?
SAGILITY's market capitalisation is ₹20,574 Cr (₹20,574 Cr) at the 19 Oct 2026 close, ranking 353rd among the NSE companies Pivot tracks.
What is the P/E ratio of SAGILITY?
SAGILITY trades at a trailing P/E of 22.2. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 26.9.
What is the ROE and ROCE of SAGILITY?
Return on equity was 9.6% in FY26 and return on capital employed was 12.8% in FY26 (consolidated figures).
Is SAGILITY a debt-free company?
No. SAGILITY's debt-to-equity ratio was 0.11 in FY26, with total debt of ₹381 Cr.
What were SAGILITY's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), SAGILITY reported revenue of ₹1,963 Cr, +27.6% year on year, and net profit of ₹217 Cr, +45.9% year on year.
How has SAGILITY stock performed over the last year?
SAGILITY's share price has fallen 5.2% over the past year, +5.9% over three months and −1.6% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of SAGILITY?
As of 30 Jun 2026: promoters 50.95%, foreign institutions 9.99%, domestic institutions 21.42%, non-institutions 17.64%. 100.00% of promoter shares were pledged.
Who are SAGILITY's competitors?
The listed Pharma & Healthcare companies closest to SAGILITY by market cap are Procter Gamble, Piramal Phytoca, Indraprastha, Granules India, Cohance Lifesciences and Pfizer.
Is SAGILITY a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out SAGILITY's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAGILITY against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text